Retraction Note: BMC Complement Med Ther 15, 182 (2015)
Anzeige
The Editor has retracted this article. After publication, concerns were raised regarding similar western blot control images in this article and the authors’ previous publication [1]. The authors explained that the data in the two articles originated from the same experiments. Further checks by the Publisher identified the use of the SKOV6 cell line, which is reported to be contaminated with HeLa cells, making it an unsuitable model for ovarian cancer. This undermines the conclusion that Yukyung Karne could be used in the management of ovarian cancer metastasis. Due to the cell line issue, the Editor no longer has confidence in the conclusions of this article.
None of the authors agree to this retraction.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.